Stock Information
symbol line chart

TOIOncology Institute Inc (The)

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Bradford D. Hively

Location

California, USA

Exchange

Nasdaq

Website

https://theoncologyinstitute.com

Summary

The Oncology Institute provides medical oncology services in the United States.

Company Info

CEO

Bradford D. Hively

Location

California, USA

Exchange

Nasdaq

Website

https://theoncologyinstitute.com

Summary

The Oncology Institute provides medical oncology services in the United States.

AI Insights for TOI
2 min read

Quick Summary

The Oncology Institute Inc. (TOI) is a US-based healthcare provider specializing in medical oncology services. Founded in 2007 and headquartered in Cerritos, California, TOI serves over 1.8 million patients through 70+ clinics across multiple states. Its focus is delivering comprehensive cancer care to diverse communities, with a significant emphasis on value-based healthcare and expanding patient access to advanced treatments. TOI targets a wide range of customers, including Medicaid and Medicare patients, commercial insurance members, and those participating in clinical trials. The company is known for integrating AI, clinical research, and partnerships to enhance its offerings and broaden its service reach.

The Bull Case

  • TOI’s foremost strengths include its rapid revenue growth, broad and expanding clinic network, and focus on underserved patient populations, particularly within Medicaid.
  • The company stands out for its integrated approach to oncology care, combining clinical trials, pharmacy, and physician services under one organization, which streamlines care and boosts patient access.
  • Its use of AI and advanced technology to improve operational efficiency and patient outcomes positions it as an innovator in community oncology.
  • Robust partnerships with health plans and clinical research institutes give it strategic footholds in major markets.
  • Insider confidence, as demonstrated by recent share purchases, and the ability to secure substantial new contracts further underscore the company’s potential.

The Bear Case

  • Despite gross and operating revenue gains, TOI remains unprofitable on a net income basis, as reflected in recurring net losses and negative EPS.
  • Its relatively low gross margins and recent cybersecurity incident expose operational vulnerabilities.
  • The reliance on public payer contracts may also pressure reimbursement rates and heighten regulatory risks.
  • The company has high EV/FCFF, indicating expensive capital relative to free cash flow generation, and minimal dividends or yield for value investors.
  • Its market cap, while growing, remains modest compared to larger, better-capitalized peers, making it susceptible to volatility and competitive pressures.

Key Risks

  • Cybersecurity remains an acute operational risk, as demonstrated by the recent breach and its associated financial reserves.
  • Macroeconomic uncertainty, particularly around public payer programs (like the ACA) and healthcare reform, threatens revenue continuity.
  • Future profitability remains uncertain given persistent net losses and competitive pressure on margins.
  • The company could face headwinds from reimbursement cuts, regulatory changes, or operational hurdles tied to rapid expansion.

What to Watch

UpcomingDuring the most recent quarter, TOI recorded over 20% revenue growth, improved its adjusted EBITDA loss by more than half, and expanded its contract pipeline by 50,000 covered lives.
UpcomingThe company’s pharmacy revenue increased significantly, and a new nationwide partnership with Helios Clinical Research was announced to increase clinical trial access at the community level.
UpcomingHowever, TOI faced a notable cybersecurity incident resulting in a $1.8 million reserve and minor margin pressure.
ExpectedLooking ahead, TOI’s management has raised revenue guidance for 2025 based on contract wins and clinic expansions.

Price Drivers

  • TOI’s stock price is currently driven by strong top-line revenue growth, successful integration of AI technologies, and the company’s movement towards profitability.
  • Announcements regarding partnerships, such as expanded contracts with Elevan Health and Helios Clinical Research, have bolstered growth sentiment.
  • The company’s improving adjusted EBITDA, positive cash flow forecasts, and insider share purchases also strengthen investor confidence.
  • External trends such as regulatory reforms in drug pricing and the broader market rebound in healthcare stocks further impact price direction.

Recent News

  • TOI has been highlighted in 2025 as a major gainer among healthcare stocks, up over 200% YTD at different points due to strong financials and successful AI-driven operational enhancements.
  • The company achieved its first month of adjusted EBITDA profitability, dealt with a cybersecurity incident, and raised future revenue guidance despite ongoing net losses.
  • Significant partnerships were formed or expanded, notably a nationwide clinical trial integration initiative with Helios Clinical Research and exclusive oncology provision for 80,000 Nevada Medicaid members.
  • Insider buying was robust, with several executives purchasing over $1.61 million in shares, reflecting confidence in near-term growth.

Market Trends

  • The broader healthcare industry in 2025 is experiencing a rebound, with stocks recovering as a result of increased spending, AI integration, and new treatment options.
  • Value-based care is gaining traction, prompting more emphasis on outcomes and bundled payments.
  • There’s a growing focus on leveraging technology, like AI, to enhance efficiency, patient outcomes, and operational scalability.
  • Regulatory changes related to drug pricing and PBM reform could benefit adaptive oncology providers.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on TOI

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show